PD Study

Investigating the Efficacy and Safety of CVT-301(Levodopa Inhalation Powder)in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena)
 
The purpose of this research is to find out whether an investigational drug called CVT-301, is helpful to people with Parkinson’s Disease (PD). The treatment involves a new method for taking levodopa (LD) through an inhaler (which is like an asthma inhaler) to provide relief of motor fluctuations (OFF episodes), which are experienced by many Parkinson’s disease patients. Patients who meet the following criteria could be eligible to participate:
 
To pre-qualify for this study, you must:
• Be between 30 and 80 years of age, inclusive
• Have a medical diagnosis of Parkinson’s disease
• Experience a minimum of 2 hours of OFF episodes per day (excluding early morning OFF time)
• Be taking oral levodopa at least 4 times during the waking day, and on a stable levodopa regimen for at least 2 weeks prior to the study
 
All study-related visits, tests, and investigational medication will be provided to participants at no cost. The study will not provide you with your current Parkinson’s medication. In addition, reimbursement for study-related time and travel may be provided.
 
If you are interested in knowing more about this clinical trial, please contact:

AMBER SERVI
Study Coordinator
212.305.3938
ads2178@cumc.columbia.edu